[Updated entry for PYMX’s data in heparin reversal.]
See MNTA ReadMeFirst for info on Lovenox and M118.
General #msg-51227061How large is the anticoagulant market? #msg-26451612 VTE is a big, big problem (Lancet 2008) #msg-26701803 Technical information on traditional anticoagulants
Pradaxa (dabigatran) #msg-51498625 Musings on Pradaxa and competitive landscape #msg-27956748 EU approves Pradaxa for VTE prevention #msg-32382343 NICE approves reimbursement for VTE prevention #msg-41018490 Pradaxa bests warfarin in AF/stroke prevention (Reuters) #msg-41014644 Pradaxa bests warfarin in AF/stroke prevention (WSJ) #msg-41024424 Pradaxa bests warfarin in AF/stroke prevention (Forbes) #msg-44244839 Phase-3 Pradaxa data in acute VTE (ASH 2009) #msg-51315844 Non-inferior to Lovenox in VTE prevention (RE-NOVATE 2) #msg-21155926 Non-inferior to Lovenox in VTE prevention (RE-NOVATE) #msg-25152872 BI starts phase-2 trial in ACS
Xarelto (rivaroxaban) #msg-52987231 Xarelto matches Lovenox in acute DVT #msg-47110232 Response to FDA’s CRL is due in 2H10 #msg-44245112 Troublesome bleeding in VTE extension study #msg-30972846 EMEA approves Xarelto for VTE prevention #msg-34103973 Phase-3 data in VTE prevention (JNJ PR) #msg-29661234 Phase-3 data in VTE prevention (Reuters) #msg-31857009 Bayer accelerates Xarelto development in ACS, but… #msg-39151366 ...Xarelto still has a long way to go in ACS! #msg-33517140 Phase-2 data in ACS #msg-29662519 Checklist rationale for Xarelto program
Apixaban #msg-51162505 Phase-3 succeeds in warfarin-free AF/stroke prevention #msg-47461590 ADVANCE-2 in VTE prevention succeeds, but… #msg-31742223 ADVANCE-1 in VTE prevention fails #msg-29928836 Phase-3 trials begin for VTE treatment #msg-32024540 Tepid phase-2 results in ACS #msg-19134406 PFE, BMY ink $1B deal to co-develop Apixaban
Edoxaban #msg-48661173 Daiichi Sankyo files for approval in Japan #msg-46218043 Largest-ever phase-3 begins in VTE prevention #msg-34100821 Phase-3 begins in AF #msg-34100787 Comparable safety to warfarin in AF (phase-2) #msg-31950663 Phase-2 data in VTE prevention after hip surgery
Betrixaban #msg-39418241 MRK licenses betrixaban (WSJ) #msg-39388813 MRK licenses betrixaban (MRK/Portola PR) #msg-47847796 Phase-2 safety data vs warfarin in AF #msg-21106352 Phase-2 data vs Lovenox in VTE prevention
Miscellaneous (in alphabetical order) #msg-41143344 Ablynx starts phase-2 of ALX-0081 in PCI #msg-40720487 Ablynx phase-1 ALX-0681 results in healthy volunteers #msg-10569101 Arixtra bests Lovenox in ACS #msg-27043616 ART-123 from Artisan Pharma #msg-39348082 ARYX’s Tecarfarin whiffs in phase-3 #msg-36811828 AZN reports phase-2 data for AZD0837 #msg-30965016 LLY terminates FXa program #msg-30353872 MYRX MPC-0920 begins phase-1 #msg-31461171 NUVO reports phase-1b data for NU172 #msg-46648382 Otamixaban ho-hum in phase-2 ACS study #msg-27187973 Paion’s Solulin completes phase-1 #msg-28742653 Paion acquires flovagatran rights #msg-50887012 PYMX phase-1b data for Lovenox reversal #msg-53193787 PYMX phase-1b/2a data for heparin reversal #msg-32171800 Regado reports phase-1 data for aptamer #msg-46648462 Sanofi’s stable of anticoagulant aspirants #msg-52169431 TB-402 (FVIII inh) bests Lovenox in VTE prevention #msg-37562465 Warfarin genetic test rejected by Medicare
News 
Market Data 
Discover 
